Patents by Inventor Martin Leuwer
Martin Leuwer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10449198Abstract: The present invention relates to a method of treating pain in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate: wherein Q is as defined herein.Type: GrantFiled: July 5, 2017Date of Patent: October 22, 2019Assignee: The University of LiverpoolInventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Patent number: 10442814Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: GrantFiled: April 13, 2018Date of Patent: October 15, 2019Assignee: University of LiverpoolInventors: Martin Leuwer, Paul M. O'Neill, Neil Berry, Chandrakala Pidathala
-
Publication number: 20190084993Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 13, 2018Publication date: March 21, 2019Applicant: The University of LiverpoolInventors: Martin Leuwer, Paul M. O'Neill, Neil Berry, Chandrakala Pidathala
-
Publication number: 20180140608Abstract: The present invention relates to a method of treating pain in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate: wherein Q is as defined herein.Type: ApplicationFiled: July 5, 2017Publication date: May 24, 2018Inventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Patent number: 9944653Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: GrantFiled: May 4, 2017Date of Patent: April 17, 2018Assignee: THE UNIVERSITY OF LIVERPOOLInventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Publication number: 20170298076Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: ApplicationFiled: May 4, 2017Publication date: October 19, 2017Inventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Patent number: 9676786Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: GrantFiled: December 23, 2014Date of Patent: June 13, 2017Assignee: THE UNIVERSITY OF LIVERPOOLInventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Publication number: 20160318947Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: ApplicationFiled: December 23, 2014Publication date: November 3, 2016Applicant: The University of LiverpoolInventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Publication number: 20160095823Abstract: The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at GABAA.Type: ApplicationFiled: November 24, 2015Publication date: April 7, 2016Applicants: The University of Liverpool, The University of Dundee, Medizinische Hochschule HannoverInventors: Martin Leuwer, Gertrud Haeseler, Jeremy Lambert, Delia Belelli
-
Patent number: 8507724Abstract: The present invention concerns compounds derived from the anaethetic propofol. The compounds may be useful in the treatment of pain, particularly, but not exclusively, chronic pain and central pain sensitisation.Type: GrantFiled: December 9, 2009Date of Patent: August 13, 2013Assignee: The University of DundeeInventors: Martin Leuwer, Paul O'Neill, Neil Berry, Gertrud Haeseler
-
Publication number: 20120029235Abstract: The present invention concerns compounds derived from the anaethetic propofol. The compounds may be useful in the treatment of pain, particularly, but not exclusively, chronic pain and central pain sensitisation.Type: ApplicationFiled: December 9, 2009Publication date: February 2, 2012Inventors: Martin Leuwer, Paul O'Neill, Neil Berry, Gertrud Haeseler
-
Patent number: 7485669Abstract: The invention relates to a pharmaceutical composition comprising at least one phenol derivative represented by formula (I) wherein R1 represents a hydrogen atom, a halogen atom or a hydrocarbon group containing up to 12 carbon atoms; R2 represents a hydrogen atom or a C1-C7 alkyl group; wherein R1 and R2 may optionally form a carbocyclic 5- or 6-membered ring; R3 represents a hydrogen atom, a halogen atom or a C1-C7alkyl group; R4 represents a hydrogen atom, a C1-C7 alkyl group or a halogen atom; R5 represents hydrogen atom, a halogen atom or a C1-C7 alkyl group; and R6 represents a hydrogen atom, a C1-C7 alkyl group or a C2 or C3 alkenyl group, under the proviso that R2 and R4 can only both represent a hydrogen atom if both R1 and R5 represent a C1-C7 alkyl group and R3 represents a halogen atom.Type: GrantFiled: November 13, 2001Date of Patent: February 3, 2009Assignee: B. Braun Melsungen AGInventors: Gertrud Haeseler, Martin Leuwer
-
Publication number: 20070142477Abstract: The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at GABAA.Type: ApplicationFiled: December 19, 2006Publication date: June 21, 2007Applicants: THE UNIVERSITY OF LIVERPOOL, THE UNIVERSITY OF DUNDEE, MEDIZINISCHE HOCHSCHULE HANNOVERInventors: Martin Leuwer, Gertrud Haeseler, Jeremy Lambert, Delia Belelli
-
Patent number: 7053176Abstract: Pharmaceutical composition for the treatment of infant respiratory distress syndrome and acute lung injury (including adult respiratory distress syndrome) which contains C1 esterase inhibitor (C1-INH) and lung surfactant which comprises a lung surfactant protein.Type: GrantFiled: September 16, 1999Date of Patent: May 30, 2006Assignee: Altana Pharma AGInventors: Dietrich Häfner, Paul-Georg Germann, Nils Ott, Burkhard Vangerow, Horst Rückoldt, Gernot Marx, Michael Cobas Meyer, Martin Leuwer
-
Publication number: 20040044084Abstract: The invention relates to a pharmaceutical composition comprising at least one phenol derivative represented by formula (I) 1Type: ApplicationFiled: September 8, 2003Publication date: March 4, 2004Inventors: Gertrud Haeseler, Martin Leuwer